OrbiMed’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $149M | Sell |
2,382,100
-37,200
| -2% | -$2.98M | 2.96% | 7 |
|
|
2025
Q4 | $231M | Sell |
2,419,300
-10,000
| -0.4% | -$980K | 4.71% | 3 |
|
|
2025
Q3 | $237M | Sell |
2,429,300
-383,900
| -14% | -$39.8M | 5.57% | 2 |
|
|
2025
Q2 | $302M | Hold |
2,813,200
| – | – | 7.55% | 2 |
|
|
2025
Q1 | $284M | Sell |
2,813,200
-347,100
| -11% | -$35M | 6.77% | 3 |
|
|
2024
Q4 | $282M | Sell |
3,160,300
-112,700
| -3% | -$9.92M | 5.81% | 3 |
|
|
2024
Q3 | $274M | Hold |
3,273,000
| – | – | 4.98% | 4 |
|
|
2024
Q2 | $252M | Hold |
3,273,000
| – | – | 4.98% | 4 |
|
|
2024
Q1 | $224M | Sell |
3,273,000
-33,800
| -1% | -$2.17M | 4.11% | 4 |
|
|
2023
Q4 | $191M | Hold |
3,306,800
| – | – | 3.82% | 4 |
|
|
2023
Q3 | $175M | Sell |
3,306,800
-73,100
| -2% | -$3.83M | 3.71% | 2 |
|
|
2023
Q2 | $183M | Sell |
3,379,900
-410,100
| -11% | -$21.4M | 3.31% | 4 |
|
|
2023
Q1 | $190M | Sell |
3,790,000
-108,200
| -3% | -$5.1M | 3.72% | 3 |
|
|
2022
Q4 | $180M | Hold |
3,898,200
| – | – | 3.45% | 4 |
|
|
2022
Q3 | $151K | Sell |
3,898,200
-471,300
| -11% | -$18.9M | 2.8% | 5 |
|
|
2022
Q2 | $163K | Sell |
4,369,500
-230,000
| -5% | -$9.36M | 2.95% | 5 |
|
|
2022
Q1 | $204M | Sell |
4,599,500
-952,800
| -17% | -$41.3M | 3.3% | 3 |
|
|
2021
Q4 | $236M | Sell |
5,552,300
-281,300
| -5% | -$11.8M | 3.03% | 4 |
|
|
2021
Q3 | $253M | Sell |
5,833,600
-1,087,000
| -16% | -$48.1M | 2.78% | 7 |
|
|
2021
Q2 | $296M | Hold |
6,920,600
| – | – | 2.99% | 4 |
|
|
2021
Q1 | $267M | Buy |
6,920,600
+397,600
| +6% | +$15M | 2.5% | 10 |
|
|
2020
Q4 | $235M | Buy |
6,523,000
+1,675,700
| +35% | +$60.4M | 2.05% | 10 |
|
|
2020
Q3 | $185M | Hold |
4,847,300
| – | – | 2.33% | 12 |
|
|
2020
Q2 | $170M | Hold |
4,847,300
| – | – | 2.4% | 12 |
|
|
2020
Q1 | $158M | Buy |
4,847,300
+172,500
| +4% | +$6.74M | 2.66% | 10 |
|
|
2019
Q4 | $211M | Sell |
4,674,800
-593,900
| -11% | -$24.9M | 3.02% | 6 |
|
|
2019
Q3 | $214M | Sell |
5,268,700
-1,483,800
| -22% | -$62.9M | 4.07% | 3 |
|
|
2019
Q2 | $290M | Buy |
6,752,500
+962,100
| +17% | +$37M | 4.49% | 3 |
|
|
2019
Q1 | $222M | Hold |
5,790,400
| – | – | 3.44% | 6 |
|
|
2018
Q4 | $205M | Sell |
5,790,400
-2,073,595
| -26% | -$75.2M | 3.78% | 5 |
|
|
2018
Q3 | $303M | Sell |
7,863,995
-1,710,700
| -18% | -$59.7M | 3.65% | 5 |
|
|
2018
Q2 | $313M | Sell |
9,574,695
-803,100
| -8% | -$24.2M | 3.73% | 4 |
|
|
2018
Q1 | $284M | Sell |
10,377,795
-8,805
| -0.1% | -$239K | 3.52% | 6 |
|
|
2017
Q4 | $257M | Sell |
10,386,600
-3,010,400
| -22% | -$83M | 3.26% | 6 |
|
|
2017
Q3 | $391M | Sell |
13,397,000
-1,003,000
| -7% | -$27.7M | 3.73% | 4 |
|
|
2017
Q2 | $399M | Sell |
14,400,000
-911,400
| -6% | -$24.2M | 4.18% | 4 |
|
|
2017
Q1 | $381M | Sell |
15,311,400
-1,195,500
| -7% | -$29.1M | 4.32% | 4 |
|
|
2016
Q4 | $357M | Sell |
16,506,900
-704,800
| -4% | -$15.4M | 4.55% | 4 |
|
|
2016
Q3 | $410M | Sell |
17,211,700
-5,917,500
| -26% | -$141M | 4.67% | 2 |
|
|
2016
Q2 | $541M | Buy |
23,129,200
+649,500
| +3% | +$14.1M | 5.64% | 1 |
|
|
2016
Q1 | $423M | Sell |
22,479,700
-1,951,200
| -8% | -$34.3M | 4.45% | 4 |
|
|
2015
Q4 | $451M | Buy |
24,430,900
+423,700
| +2% | +$7.59M | 4.08% | 3 |
|
|
2015
Q3 | $394M | Buy |
24,007,200
+2,327,200
| +11% | +$39.8M | 3.98% | 4 |
|
|
2015
Q2 | $384M | Buy |
21,680,000
+8,169,000
| +60% | +$146M | 3.21% | 8 |
|
|
2015
Q1 | $240M | Buy |
13,511,000
+13,191,000
| +4,122% | +$208M | 2.05% | 17 |
|
|
2014
Q4 | $4.24M | Buy |
320,000
+48,300
| +18% | +$617K | 0.04% | 113 |
|
|
2014
Q3 | $3.21M | Hold |
271,700
| – | – | 0.03% | 118 |
|
|
2014
Q2 | $3.47M | Hold |
271,700
| – | – | 0.04% | 118 |
|
|
2014
Q1 | $3.67M | Buy |
+271,700
| New | +$3.57M | 0.05% | 125 |
|
|
2013
Q4 | – | Sell |
-170,000
| Closed | -$2M | – | 124 |
|
|
2013
Q3 | $2M | Buy |
+170,000
| New | +$1.84M | 0.04% | 121 |
|
Other funds holding BSX
VCM
VPM
OrbiMed's BSX Position: Q1 2026 in Review
OrbiMed reduced its Boston Scientific (BSX) stake by 1.5% in Q1 2026, selling an estimated $2.98M and leaving 2,382,100 shares worth $149M. The position accounts for 2.96% of the portfolio, ranked #7.
OrbiMed first reported a position in BSX in Q3 2013 and has held it in 50 quarters since. The position peaked at $541M in Q2 2016. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- OrbiMed held 2,382,100 shares of Boston Scientific worth $149M as of Q1 2026.
- OrbiMed sold 37,200 Boston Scientific shares in Q1 2026, an estimated $2.98M.
- Boston Scientific made up 2.96% of OrbiMed's portfolio in Q1 2026, its #7 holding.
- OrbiMed first reported a position in Boston Scientific in Q3 2013 and has held it in 50 quarters since.
- OrbiMed's Boston Scientific position peaked at $541M in Q2 2016.
- 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.